Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Multiple Ascending Dose Study of Milademetan in Subjects With Advanced Solid Tumors or Lymphomas

Trial Profile

A Phase 1 Multiple Ascending Dose Study of Milademetan in Subjects With Advanced Solid Tumors or Lymphomas

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 20 Feb 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Milademetan (Primary)
  • Indications Diffuse large B cell lymphoma; Liposarcoma; Lymphoma; Malignant melanoma; Sarcoma; Solid tumours; Synovial sarcoma
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors Daiichi Sankyo Company; Daiichi Sankyo Inc
  • Most Recent Events

    • 23 Mar 2023 Results assessing the safety profile and management of adverse events of milademetan from U101; NCT01877382 and MANTRA-2; NCT05012397 studies, presented at the British Sarcoma Group (BSG) Conference.
    • 21 Mar 2023 According to Rain Oncology media release, a copy of the presentation materials containing data from this study can be accessed by visiting the Resources section of the Rain website after the conclusion of the presentation and will be archived on the Rain website
    • 23 Jan 2023 Results published in the Rain Oncology media release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top